Wilson A P
Department of Clinical Microbiology, University College Hospital, London, UK.
Int J Antimicrob Agents. 1998 May;10(2):143-52. doi: 10.1016/s0924-8579(98)00025-9.
Teicoplanin have different safety profiles which can affect choice. Nephrotoxicity is significantly less likely to occur during treatment with teicoplanin than vancomycin when an aminoglycoside is being given concurrently. 'Red man' syndrome is a troublesome effect of vancomycin infusion which is extremely uncommon with teicoplanin use. Rash and fever can be dose-related phenomena but patients reacting to one glycopeptide may not react to both. Although thrombocytopenia is more frequent with teicoplanin, it is reversible and seldom seen at standard doses.
替考拉宁具有不同的安全性特征,这会影响用药选择。当同时使用氨基糖苷类药物时,与万古霉素相比,替考拉宁治疗期间发生肾毒性的可能性显著降低。“红人”综合征是万古霉素输注时令人困扰的不良反应,而使用替考拉宁时极为罕见。皮疹和发热可能与剂量相关,但对一种糖肽有反应的患者不一定对另一种也有反应。虽然替考拉宁导致血小板减少症更为常见,但它是可逆的,在标准剂量下很少出现。